Klaria Pharma Holding AB Partners with Chilam Enterprise Ltd To Power Expansion to Medical Cannabis Sector
Stockholm and London, August 6th, 2020 I Klaria Pharma Holding AB and its subsidiary company Cannabis Delivery Sciences(CDS) today announced that Chilam Enterprise Ltd has entered into a non-exclusive license agreement with CDS for the right to sell CDS’ Cannabis Alginate Films in Europe. Starting in 2021, Chilam will supply the European medical sector with GMP-compliant medical cannabis formulated in the Alginate Film.
Chilam specialises in cannabis research, cultivation, production and distribution. Focused on developing science-backed medical and derivative cannabis products, Chilam is using Genofarm’s expertise in seeds genetics to commit to produce GMP-compliant medical cannabis - both dried flower and oil - in accordance with European Union standards, in its manufacturing facility in North Macedonia. Chilam will supply the European medical sector with medicinal cannabis both as a white label manufacturer to third parties and as directly under its own brands.
This partnership will enable Chilam to export a greater range of medical cannabis products that includes the Alginate Film to international patients and markets with legal medical cannabis regulations. By combining the next-generation CDS delivery technology with Chilam’s highly standardized quality cannabis strains, Chilam aims to acquire significant market-share in the European medical cannabis sector.
“Europe is undergoing a wave of regulatory and legislative changes and the market is moving quickly, with several European countries introducing or announcing future legislation to advance the legal cannabis agenda. It is an exciting time for us as we have an optimal delivery technology which is patented and brings pharma-grade delivery precision to the sector. It is our goal to become the de-facto delivery technology in the Medicinal Cannabis industry. Working alongside Chilam, who share our passion for quality and regulatory controls in the sector, we are moving towards that goal.”, says Scott de Mercado, Co-founder & Head of Business Development at Cannabis Delivery Sciences.
“As demand increases around the world and more legal medical cannabis markets emerge, we are thrilled to partner with Cannabis Delivery Services to reaffirm our commitment to delivering medical cannabis to patients and the pharmaceutical industry. This is an important milestone for our strategic growth in the international medical cannabis market. We look forward to supplying pharmaceutical-grade cannabis products, proudly produced in North-Macedonia. The Cannabis Alginate Film will be an important part in our product portfolio”, says George Meek, CEO & co-founder at Chilam Enterprise Ltd.
About Cannabis Delivery Sciences
Cannabis Delivery Sciences is a subsidiary of Klaria Pharma Holding AB (publ), and has secured an exclusive and perpetual world-wide license to Klaria’s Alginate Film Technology for both medicinal and recreational use of all cannabinoids, including CBD and THC. The company is led by an international management team with experience from the United States, Canada, Jamaica, and the UK in entrepreneurial companies focused on the marketing of luxury goods and high-end spirits as well as on pharmaceutical development.
More information: https://cannabisdeliverysciences.com/
About Chilam
Enterprising visionaries with deep industry knowledge, scientific and technical expertise, Chilam was founded in 2019 with the vision to bring premium and effective cannabis products to the medical-use market. Our team of experts and international business leaders formed a solid business model leveraging the emerging European market to become the leading medical cannabis producer and distributor in Europe.
More information: https://chil.am/ Contact us: info@chil.am
About Genofarm
Genofarm has more than 15 years breeding experience in the hemp industry. Our genetics are sourced and selected from the purest strains to ensure the best quality. We work with high end hemp experts to keep up with a knowledgeable and demanding public. To ensure high end quality, we look for well structured varieties that have special rarities and colorful polychromes. We constantly test our genetics to ensure they function in extreme conditions with high and low temperatures. Our seeds are made up from a truly composite gene pool which provides stable varieties of land race strains, pure bred plants, elite clones and hybrids.
More information: https://www.genofarm.com/en/
For more information, visit the Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99
This is Klaria Pharma Holding AB
Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.